The maze of treatments for hepatitis B.

  title={The maze of treatments for hepatitis B.},
  author={A S Lok},
  journal={The New England journal of medicine},
  volume={352 26},
  • A S Lok
  • Published 2005 in The New England journal of medicine
Worldwide, there are approximately 350 million carriers of hepatitis B virus (HBV), of whom half a million to 1 million die from liver disease each year. The goal of treatment for chronic hepatitis B is to prevent cirrhosis, hepatic failure, and hepatocellular carcinoma. This goal is best achieved by eradicating HBV before irreversible liver damage occurs. However, the eradication of HBV is impossible to achieve because of the presence of extrahepatic reservoirs of HBV, the integration of HBV… CONTINUE READING

From This Paper

Figures and tables from this paper.


Publications citing this paper.
Showing 1-10 of 36 extracted citations

Autoimmune hepatitis in a child with chronic hepatitis B virus infection.

Journal of pediatric gastroenterology and nutrition • 2009
View 4 Excerpts
Highly Influenced

Chronic HBV Carrier’s acceptance of regular surveilling program in China

Journal of Huazhong University of Science and Technology [Medical Sciences] • 2013


Publications referenced by this paper.
Showing 1-10 of 12 references

A randomized , controlled trial of combination therapy for chronic hepatitis B : comparing pegylated interferon - alpha 2 b and lamivudine with lamivudine alone

SK Fung, F Wong, M Hussain, AS Lok
Ann Intern Med • 2005

Similar Papers

Loading similar papers…